Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAIRO3: Maintenance Capecitabine + Bevacizumab in mCRC
NCT00442637Phase 3Unknown
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Jan 2007
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine, bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Dutch Colorectal Cancer Group. Status: unknown.
02
Drugs
capecitabinebevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00442637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00442637.